Eprogen | GenomeWeb


According to Matthew Kuruc, COO of PIN member ProFact Proteomics, the network aims to help smaller firms offer complete solutions similar to those increasingly provided by large instrument vendors and to popularize non-mass spec-based proteomics workflows.

Although it's too early to announce biopharma partners, the 13 companies involved in the network are hoping that their collective skills and specialties will attract companies interested in developing drugs targeted to specific proteomic markers in patients.

The group aims to provide solutions for all stages of proteomics research and address "critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring."

Over the past week, OGT acquired protein-array maker Sense Proteomic, Aushon bought Thermo's SearchLight protein-array business, and Gentel and Eprogen allied to help drug makers identify new autoantibody biomarkers.

Industry Briefs


Gentel, Eprogen, Novozymes, Proteome Sciences, Pepsca, Advanced Proteome Therapeutics, AnaSpec

Gentel and Eprogen will combine their respective technologies to make whole proteome microarrays for identifying new autoantibody biomarkers.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.